New Delhi, July 9 -- Novo Nordisk India on Thursday announced the launch in India of Awiqli (insulin icodec), the world's first weekly once-basal insulin for adults with Type 1 or Type 2 diabetes mellitus. The product reduces the insulin regimen from once-daily to once-weekly - or 365 shots to 52.

The company describes this as a fundamental reimagining of how insulin fits into people's lives rather than an incremental improvement.

In the global ONWARDS-1 clinical programme, Awiqli demonstrated superior HbA1c reduction and increased Time in Range compared with once-daily glargine U100. More people with Type 2 diabetes achieved an HbA1c level below 7% without hypoglycaemia, while the significant improvement in Time in Range provided patie...